Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA.
Justin D Finkle, Hala Boulos, Terri M Driessen...
https://pubmed.ncbi.nlm.nih.gov/34215841/Actively Recruiting
Led by Tempus AI · Updated on 2026-02-24
500
Participants Needed
32
Research Sites
N/A
Total Duration
Researchers are evaluating participants with cancer in a non-interventional, multicenter, multicohort study to observe plasma circulating tumor DNA ctDNA biomarker changes over time. This study aims to gather valuable data alongside participants standard cancer treatments to better understand cancer biology. The study is sponsored by Tempus AI and focuses on various cancer types including KRAS mutated colorectal, pancreatic, and lung cancers, gastric cancer, metastatic prostate cancer, and others. Participants in this observational study will not receive any study interventions or treatments. Instead, they will provide blood samples at specific time points throughout their treatment journey for ctDNA analysis and other molecular studies. The study includes multiple cohorts representing different cancer types, but no additional therapies are assigned by the study team. During the study, participants will undergo regular blood draws to monitor ctDNA levels at baseline, during treatment, and after treatment for up to five years. Researchers will also generate DNA, RNA, immune, and other molecular datasets from these samples. The study involves no experimental treatments, focusing on data collection to support future cancer research. Participation may last up to five years, with ongoing monitoring of biomarker changes and data generation.
CONDITIONS
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
L
Lauren Lopez
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tempus AI
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants provide blood samples over time to monitor changes in ctDNA and other biological markers.
Periodic blood sample collections over 5 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
7
Have more questions? Get in touch with our team for quick support
Justin D Finkle, Hala Boulos, Terri M Driessen...
https://pubmed.ncbi.nlm.nih.gov/34215841/Nike Beaubier, Martin Bontrager, Robert Huether...
https://pubmed.ncbi.nlm.nih.gov/31570899/Nike Beaubier, Robert Tell, Denise Lau...
https://pubmed.ncbi.nlm.nih.gov/31040929/Christopher Abbosh, Nicolai J Birkbak, Charles Swanton
https://pubmed.ncbi.nlm.nih.gov/29968853/Paz J Vellanki, Soma Ghosh, Anand Pathak...
https://pubmed.ncbi.nlm.nih.gov/36796877/Tempus AI
Lead Sponsor